Effects of Integrase Inhibitor–Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV

Abstract The NOD-like receptor protein family pyrin domain containing 3 (NLRP3) inflammasome, activated in the setting of HIV, contributes to pro-atherogenic inflammation. Among antriretroviral therapy–naïve people with HIV (vs controls), levels of caspase-1—a key component of the NLRP3 inflammasome...

Full description

Saved in:
Bibliographic Details
Published in:Open forum infectious diseases 2020-10, Vol.7 (10), p.ofaa459-ofaa459
Main Authors: Toribio, Mabel, Burdo, Tricia H, Fulda, Evelynne S, Cetlin, Madeline, Chu, Sarah M, Feldpausch, Meghan N, Robbins, Gregory K, Neilan, Tomas G, Melbourne, Kathleen, Grinspoon, Steven K, Zanni, Markella V
Format: Article
Language:English
Subjects:
Brief Reports
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The NOD-like receptor protein family pyrin domain containing 3 (NLRP3) inflammasome, activated in the setting of HIV, contributes to pro-atherogenic inflammation. Among antriretroviral therapy–naïve people with HIV (vs controls), levels of caspase-1—a key component of the NLRP3 inflammasome—were significantly increased. Six months of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate significantly decreased caspase-1 levels in association with CD4+/CD8+ ratio recovery. Trial registration. ClinicalTrials.gov NCT 01766726.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofaa459